Despite the fact that DUSP1 and DUSP6 have been studied in detail and there are inhibitors available, further extensive work is needed to better understand the role of all ERK-targeting DUSPs within the various types of tumours and to develop DUSP modulators, both inhibitors and activators, for their utilization in the clinics. This evidence concerns the gene MAPK1 and neoplasm.